Human Coagulation Factor VII Market Research Report from 2023 forecast to 2029, by Manufacturers, Regions, Type and Application

The global Human Coagulation Factor VII market size was valued at USD 2348.5 million in 2022 and is forecast to a readjusted size of USD 4345 million by 2029 with a CAGR of 9.2% during review period.

Human Coagulation Factor VII is one of the proteins that cause blood to clot in the coagulation cascade. It is an enzyme of the serine protease class. It is sometimes used unlicensed in severe uncontrollable bleeding, although there have been safety concerns. A bio similar form of recombinant activated factor VII is also available, but does not play any considerable role in the market.

Europe and North America are the largest region of Human Coagulation Factor VII, with about 40% market share respectively. NovoNordisk is the major manufacturer of industry. This report is a detailed and comprehensive analysis for global Human Coagulation Factor VII market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.

Key Features:

Global Human Coagulation Factor VII market size and forecasts, in consumption value ($ Million), sales quantity (K Mg), and average selling prices (USD/Kg), 2018-2029
Global Human Coagulation Factor VII market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Mg), and average selling prices (USD/Kg), 2018-2029
Global Human Coagulation Factor VII market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Mg), and average selling prices (USD/Kg), 2018-2029
Global Human Coagulation Factor VII market shares of main players, shipments in revenue ($ Million), sales quantity (K Mg), and ASP (USD/Kg), 2018-2023

The Primary Objectives in This Report Are:

To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Human Coagulation Factor VII
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace

This report profiles key players in the global Human Coagulation Factor VII market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

   NovoNordisk

   Recombinant Factor VIII
   Plasma-derived Factor VIII

   Hemophilia A
   Spontanous / Trauma
   Surgical
   Others

   North America (United States, Canada and Mexico)
   Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
   Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
   South America (Brazil, Argentina, Colombia, and Rest of South America)
   Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

What are the strengths of the Human Coagulation Factor VII market in 2025?

The market's strength lies in the increasing global demand for therapies related to bleeding disorders, particularly hemophilia. Advancements in biotechnology and personalized medicine are improving the efficacy of treatments, while ongoing clinical trials and approvals are expanding product offerings. Additionally, the growing awareness of rare diseases and the need for precise treatment options contribute to the market's strength.

What weaknesses could the Human Coagulation Factor VII market face in 2025?

One key weakness could be the high cost of Factor VII therapies, which may limit access in lower-income regions or developing countries. Regulatory challenges and the complexity of developing and manufacturing recombinant clotting factors can also slow market growth. Furthermore, the limited number of treatments available for specific bleeding disorders might restrict market potential.

What opportunities exist for the Human Coagulation Factor VII market in 2025?

Opportunities lie in expanding treatment options through innovative therapies, such as gene therapy, and further improving existing products for better patient outcomes. There is also a potential market in emerging economies where healthcare infrastructure is evolving. Additionally, partnerships between biotech companies and healthcare providers to create more accessible treatment plans could further boost market growth.

What threats might impact the Human Coagulation Factor VII market in 2025?

Competitive pressures from alternative therapies, such as gene therapies or novel anticoagulants, could impact the market share of traditional Factor VII treatments. Moreover, evolving healthcare policies and price regulation frameworks in various regions may hinder market expansion. The market might also face challenges from regulatory delays and unforeseen safety concerns linked to new treatments.

What political factors could impact the Human Coagulation Factor VII market in 2025?

Political factors such as healthcare policies, government funding for rare diseases, and regulatory frameworks will significantly influence the market. Changes in reimbursement rates or healthcare coverage for coagulation treatments could affect market access and growth. Additionally, political instability in certain regions may hinder the distribution of essential therapies.

What economic factors could affect the Human Coagulation Factor VII market in 2025?

The economic environment, including healthcare expenditure, pricing strategies, and economic stability in different regions, will affect the affordability and accessibility of Factor VII therapies. In developed countries, high treatment costs could be a barrier for patients without comprehensive insurance coverage. In emerging markets, economic growth and increased healthcare budgets may create opportunities for market expansion.

What social factors will influence the Human Coagulation Factor VII market in 2025?

Growing awareness of bleeding disorders and their treatment options, particularly among healthcare professionals and patients, will drive market demand. Social factors like an aging population, increased patient advocacy, and the shift toward personalized healthcare are also key trends. Social acceptance of advanced therapies, including gene therapy, will further impact the market’s growth.

What technological factors could affect the Human Coagulation Factor VII market in 2025?

Technological advancements in biotechnology, such as improvements in recombinant protein production and the development of gene therapies, are transforming the treatment landscape. Innovations in drug delivery systems and diagnostic tools will also improve treatment efficacy. However, the need for continuous research and technological development to address safety and efficacy concerns remains a challenge.

What environmental factors might influence the Human Coagulation Factor VII market in 2025?

Environmental factors like sustainability and climate change may have a secondary impact on production processes and supply chains. Biopharmaceutical companies may face pressure to adopt greener production methods or meet environmental regulations. The increasing demand for environmentally responsible manufacturing could alter cost structures and operational strategies in the market.

What legal factors could affect the Human Coagulation Factor VII market in 2025?

Legal considerations, including intellectual property rights, patent expirations, and regulatory approvals, will play a significant role. Stricter regulations regarding drug safety, efficacy, and labeling can impact the time to market for new treatments. Additionally, legal disputes related to patents or market exclusivity could influence competition within the industry.

Who are the suppliers in the Human Coagulation Factor VII market in 2025?

Suppliers in this market include biotechnology and pharmaceutical companies that produce recombinant clotting factors, raw material providers for manufacturing, and research organizations that develop new treatments. Additionally, suppliers of medical equipment and diagnostic tools that support coagulation therapy are key contributors to the supply chain.

What inputs are necessary for the Human Coagulation Factor VII market in 2025?

Inputs include advanced biotechnological research, raw materials for drug production, regulatory compliance, and clinical trial data. Intellectual property, manufacturing technologies, and partnerships with healthcare institutions are also critical inputs in the development and distribution of Human Coagulation Factor VII therapies.

Who are the process stakeholders in the Human Coagulation Factor VII market in 2025?

The process stakeholders include pharmaceutical companies responsible for the development and manufacturing of the therapies, healthcare providers who administer the treatments, regulatory bodies that ensure safety and efficacy, and research organizations driving innovation in coagulation therapies. Patients and their advocacy groups are also integral to the process as they influence demand and treatment protocols.

What are the outputs in the Human Coagulation Factor VII market in 2025?

The primary outputs are advanced coagulation factor VII therapies, including recombinant and engineered clotting factors, as well as diagnostic tests and medical devices used in treatment. These outputs lead to better management of bleeding disorders and improved patient outcomes. Additionally, research findings and clinical trial results are outputs that help shape future therapies.

Who are the customers of the Human Coagulation Factor VII market in 2025?

The customers include healthcare providers such as hospitals, clinics, and specialty care centers that treat bleeding disorders. Insurance companies, government health organizations, and private sector players are customers who fund and facilitate access to these therapies. End customers are patients suffering from bleeding disorders like hemophilia who rely on these treatments for improved quality of life.

How strong is the threat of new entrants in the Human Coagulation Factor VII market in 2025?

The threat of new entrants is moderate to low. The market is highly specialized, requiring significant investment in biotechnology, regulatory approvals, and research. The complex nature of developing effective coagulation therapies, along with the strong presence of established players, creates high barriers to entry. However, advancements in biotechnology and partnerships could enable some new players to enter the market.

How intense is the bargaining power of suppliers in the Human Coagulation Factor VII market in 2025?

The bargaining power of suppliers is moderate. While there are several suppliers of raw materials and manufacturing technologies, the specialized nature of the ingredients needed for recombinant clotting factors limits the number of suppliers. However, as competition in biotech increases, there may be opportunities for companies to negotiate better terms, reducing supplier power.

How strong is the bargaining power of buyers in the Human Coagulation Factor VII market in 2025?

The bargaining power of buyers is moderate. Patients and healthcare providers are increasingly seeking more affordable and effective therapies, but due to the specialized nature of Factor VII treatments and the lack of direct substitutes, buyers have limited negotiating power. However, large healthcare providers and insurance companies may have more influence in price negotiations.

What is the threat of substitute products or services in the Human Coagulation Factor VII market in 2025?

The threat of substitutes is moderate. While gene therapies and newer anticoagulants show promise, Factor VII therapies remain essential for certain bleeding disorders. However, as alternative treatments, such as gene therapy and novel clotting factor products, continue to develop, the risk of substitution increases, especially if they prove more effective or less expensive.

How intense is the rivalry among existing competitors in the Human Coagulation Factor VII market in 2025?

Rivalry among existing competitors is high. The market is dominated by a few key players, and as demand for coagulation therapies grows, competition for market share increases. Companies are constantly innovating and refining their therapies to improve efficacy and reduce costs. Regulatory hurdles, pricing pressures, and the need for continuous clinical trials further intensify the competitive landscape.

What are the key raw materials involved in the Human Coagulation Factor VII market in 2025?

The key raw materials include recombinant DNA, cell culture media, growth factors, and various biotechnological components required for the production of clotting factors. The quality and sourcing of these materials are critical to ensuring the safety, efficacy, and cost-effectiveness of the therapies.

What are the major suppliers in the upstream segment of the Human Coagulation Factor VII market in 2025?

Major suppliers in the upstream segment include biotechnology companies that specialize in genetic engineering and recombinant protein production, as well as suppliers of cell culture systems, bioreactors, and raw materials for protein purification. These suppliers play a crucial role in the early stages of the development and manufacturing process for coagulation therapies.

What technological advancements are driving the upstream processes in the Human Coagulation Factor VII market in 2025?

Advancements in gene editing, cell culture optimization, and protein purification technologies are significantly improving the production of coagulation factors. Innovations in bioreactor design and the use of artificial intelligence in research and development processes also enhance the efficiency and scalability of manufacturing, driving down production costs.

How do regulatory challenges impact the upstream processes in the Human Coagulation Factor VII market in 2025?

Regulatory challenges, including stringent safety and quality control standards, impact the upstream processes by requiring extensive testing, validation, and compliance with local and international guidelines. These regulations can lengthen development timelines, increase costs, and limit the flexibility of production methods, making regulatory navigation a key challenge for suppliers.

What risks do upstream suppliers face in the Human Coagulation Factor VII market in 2025?

Upstream suppliers face risks related to raw material shortages, supply chain disruptions, and the rising costs of production. Additionally, strict regulatory scrutiny and the complexity of scaling up biotechnological processes can create bottlenecks. Environmental concerns and sustainability pressures may also affect suppliers, requiring more eco-friendly production practices.

What are the key processes in the midstream segment of the Human Coagulation Factor VII market in 2025?

The key processes in the midstream segment involve the purification, formulation, and packaging of Human Coagulation Factor VII products. These stages include the refining of recombinant proteins, quality control testing, and ensuring that the final product meets regulatory standards before it moves to distribution.

How do manufacturing and production capabilities impact the Human Coagulation Factor VII market in 2025?

Manufacturing and production capabilities are crucial in determining the scalability, cost-efficiency, and quality of Factor VII therapies. High-capacity, automated manufacturing systems can reduce production costs, increase supply chain efficiency, and ensure consistent product quality. These capabilities will help meet the growing demand for coagulation factor therapies in various regions.

What role do quality control and regulatory compliance play in the midstream processes of the Human Coagulation Factor VII market in 2025?

Quality control and regulatory compliance are critical to ensuring the safety, efficacy, and consistency of Factor VII therapies. Adherence to Good Manufacturing Practices (GMP) and meeting regulatory standards set by agencies like the FDA and EMA are essential to avoid delays in approval and ensure patient safety. These processes directly impact the success and market acceptance of the products.

What are the key challenges faced in the midstream segment of the Human Coagulation Factor VII market in 2025?

Key challenges include maintaining consistent production quality, ensuring efficient supply chain management, and managing the costs associated with stringent regulatory requirements. Additionally, scaling up production to meet increasing demand without compromising quality or safety can be difficult. Supply chain disruptions or raw material shortages could also affect production timelines.

How are technological innovations impacting the midstream segment of the Human Coagulation Factor VII market in 2025?

Technological innovations, such as automated bioreactors, continuous manufacturing techniques, and advanced purification systems, are improving the efficiency and scalability of production. These technologies allow for faster processing times, greater consistency in product quality, and cost reduction, ultimately benefiting the overall midstream segment and the availability of coagulation therapies.

What are the key activities in the downstream segment of the Human Coagulation Factor VII market in 2025?

The key activities in the downstream segment include distribution, marketing, sales, and patient support services. These activities focus on getting the final product to healthcare providers, ensuring it reaches patients efficiently, and supporting their ongoing treatment needs. Additionally, post-market surveillance and patient monitoring are crucial for assessing the long-term effectiveness of the therapies.

How does distribution impact the Human Coagulation Factor VII market in 2025?

Distribution plays a vital role in ensuring that Factor VII therapies are available in a timely manner across various regions. Efficient distribution networks help prevent stockouts, reduce delays, and ensure that patients receive their treatments without interruption. Global and regional distribution strategies must also account for storage conditions, as some coagulation factors require cold-chain handling.

What role does marketing and sales play in the downstream segment of the Human Coagulation Factor VII market in 2025?

Marketing and sales are essential for driving demand, educating healthcare providers, and raising awareness about bleeding disorders and treatment options. Companies must engage in targeted marketing campaigns to reach healthcare professionals and patients, emphasizing the effectiveness, safety, and accessibility of their Factor VII products. Sales strategies also involve negotiation with healthcare providers and insurance companies.

What are the challenges in the downstream segment of the Human Coagulation Factor VII market in 2025?

Challenges include maintaining an efficient supply chain, navigating complex reimbursement policies, and ensuring product accessibility in different regions, especially in low-income countries. Marketing efforts may also be hindered by competition from other therapies and regulatory hurdles. Additionally, addressing the affordability of treatments remains a significant challenge for both manufacturers and patients.

How are patient support services affecting the downstream segment of the Human Coagulation Factor VII market in 2025?

Patient support services are increasingly important in the downstream segment as they help ensure adherence to treatment regimens, provide educational resources, and offer financial assistance programs. These services improve patient outcomes by providing personalized care and support, enhancing customer loyalty, and fostering better engagement with healthcare providers.

Chapter 1, to describe Human Coagulation Factor VII product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Human Coagulation Factor VII, with price, sales, revenue and global market share of Human Coagulation Factor VII from 2018 to 2023.
Chapter 3, the Human Coagulation Factor VII competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Human Coagulation Factor VII breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022.and Human Coagulation Factor VII market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.
Chapter 12, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War.
Chapter 13, the key raw materials and key suppliers, and industry chain of Human Coagulation Factor VII.
Chapter 14 and 15, to describe Human Coagulation Factor VII sales channel, distributors, customers, research findings and conclusion.

1 Market Overview

   1.1 Product Overview and Scope of Human Coagulation Factor VII
   1.2 Market Estimation Caveats and Base Year
   1.3 Market Analysis by Type
       1.3.1 Overview: Global Human Coagulation Factor VII Consumption Value by Type: 2018 Versus 2022 Versus 2029
       1.3.2 Recombinant Factor VIII
       1.3.3 Plasma-derived Factor VIII
   1.4 Market Analysis by Application
       1.4.1 Overview: Global Human Coagulation Factor VII Consumption Value by Application: 2018 Versus 2022 Versus 2029
       1.4.2 Hemophilia A
       1.4.3 Spontanous / Trauma
       1.4.4 Surgical
       1.4.5 Others
   1.5 Global Human Coagulation Factor VII Market Size & Forecast
       1.5.1 Global Human Coagulation Factor VII Consumption Value (2018 & 2022 & 2029)
       1.5.2 Global Human Coagulation Factor VII Sales Quantity (2018-2029)
       1.5.3 Global Human Coagulation Factor VII Average Price (2018-2029)

2 Manufacturers Profiles

   2.1 NovoNordisk
       2.1.1 NovoNordisk Details
       2.1.2 NovoNordisk Major Business
       2.1.3 NovoNordisk Human Coagulation Factor VII Product and Services
       2.1.4 NovoNordisk Human Coagulation Factor VII Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
       2.1.5 NovoNordisk Recent Developments/Updates

3 Competitive Environment: Human Coagulation Factor VII by Manufacturer

   3.1 Global Human Coagulation Factor VII Sales Quantity by Manufacturer (2018-2023)
   3.2 Global Human Coagulation Factor VII Revenue by Manufacturer (2018-2023)
   3.3 Global Human Coagulation Factor VII Average Price by Manufacturer (2018-2023)
   3.4 Market Share Analysis (2022)
       3.4.1 Producer Shipments of Human Coagulation Factor VII by Manufacturer Revenue ($MM) and Market Share (%): 2022
       3.4.2 Top 3 Human Coagulation Factor VII Manufacturer Market Share in 2022
       3.4.2 Top 6 Human Coagulation Factor VII Manufacturer Market Share in 2022
   3.5 Human Coagulation Factor VII Market: Overall Company Footprint Analysis
       3.5.1 Human Coagulation Factor VII Market: Region Footprint
       3.5.2 Human Coagulation Factor VII Market: Company Product Type Footprint
       3.5.3 Human Coagulation Factor VII Market: Company Product Application Footprint
   3.6 New Market Entrants and Barriers to Market Entry
   3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

   4.1 Global Human Coagulation Factor VII Market Size by Region
       4.1.1 Global Human Coagulation Factor VII Sales Quantity by Region (2018-2029)
       4.1.2 Global Human Coagulation Factor VII Consumption Value by Region (2018-2029)
       4.1.3 Global Human Coagulation Factor VII Average Price by Region (2018-2029)
   4.2 North America Human Coagulation Factor VII Consumption Value (2018-2029)
   4.3 Europe Human Coagulation Factor VII Consumption Value (2018-2029)
   4.4 Asia-Pacific Human Coagulation Factor VII Consumption Value (2018-2029)
   4.5 South America Human Coagulation Factor VII Consumption Value (2018-2029)
   4.6 Middle East and Africa Human Coagulation Factor VII Consumption Value (2018-2029)

5 Market Segment by Type

   5.1 Global Human Coagulation Factor VII Sales Quantity by Type (2018-2029)
   5.2 Global Human Coagulation Factor VII Consumption Value by Type (2018-2029)
   5.3 Global Human Coagulation Factor VII Average Price by Type (2018-2029)

6 Market Segment by Application

   6.1 Global Human Coagulation Factor VII Sales Quantity by Application (2018-2029)
   6.2 Global Human Coagulation Factor VII Consumption Value by Application (2018-2029)
   6.3 Global Human Coagulation Factor VII Average Price by Application (2018-2029)

7 North America

   7.1 North America Human Coagulation Factor VII Sales Quantity by Type (2018-2029)
   7.2 North America Human Coagulation Factor VII Sales Quantity by Application (2018-2029)
   7.3 North America Human Coagulation Factor VII Market Size by Country
       7.3.1 North America Human Coagulation Factor VII Sales Quantity by Country (2018-2029)
       7.3.2 North America Human Coagulation Factor VII Consumption Value by Country (2018-2029)
       7.3.3 United States Market Size and Forecast (2018-2029)
       7.3.4 Canada Market Size and Forecast (2018-2029)
       7.3.5 Mexico Market Size and Forecast (2018-2029)

8 Europe

   8.1 Europe Human Coagulation Factor VII Sales Quantity by Type (2018-2029)
   8.2 Europe Human Coagulation Factor VII Sales Quantity by Application (2018-2029)
   8.3 Europe Human Coagulation Factor VII Market Size by Country
       8.3.1 Europe Human Coagulation Factor VII Sales Quantity by Country (2018-2029)
       8.3.2 Europe Human Coagulation Factor VII Consumption Value by Country (2018-2029)
       8.3.3 Germany Market Size and Forecast (2018-2029)
       8.3.4 France Market Size and Forecast (2018-2029)
       8.3.5 United Kingdom Market Size and Forecast (2018-2029)
       8.3.6 Russia Market Size and Forecast (2018-2029)
       8.3.7 Italy Market Size and Forecast (2018-2029)

9 Asia-Pacific

   9.1 Asia-Pacific Human Coagulation Factor VII Sales Quantity by Type (2018-2029)
   9.2 Asia-Pacific Human Coagulation Factor VII Sales Quantity by Application (2018-2029)
   9.3 Asia-Pacific Human Coagulation Factor VII Market Size by Region
       9.3.1 Asia-Pacific Human Coagulation Factor VII Sales Quantity by Region (2018-2029)
       9.3.2 Asia-Pacific Human Coagulation Factor VII Consumption Value by Region (2018-2029)
       9.3.3 China Market Size and Forecast (2018-2029)
       9.3.4 Japan Market Size and Forecast (2018-2029)
       9.3.5 Korea Market Size and Forecast (2018-2029)
       9.3.6 India Market Size and Forecast (2018-2029)
       9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
       9.3.8 Australia Market Size and Forecast (2018-2029)

10 South America

   10.1 South America Human Coagulation Factor VII Sales Quantity by Type (2018-2029)
   10.2 South America Human Coagulation Factor VII Sales Quantity by Application (2018-2029)
   10.3 South America Human Coagulation Factor VII Market Size by Country
       10.3.1 South America Human Coagulation Factor VII Sales Quantity by Country (2018-2029)
       10.3.2 South America Human Coagulation Factor VII Consumption Value by Country (2018-2029)
       10.3.3 Brazil Market Size and Forecast (2018-2029)
       10.3.4 Argentina Market Size and Forecast (2018-2029)

11 Middle East & Africa

   11.1 Middle East & Africa Human Coagulation Factor VII Sales Quantity by Type (2018-2029)
   11.2 Middle East & Africa Human Coagulation Factor VII Sales Quantity by Application (2018-2029)
   11.3 Middle East & Africa Human Coagulation Factor VII Market Size by Country
       11.3.1 Middle East & Africa Human Coagulation Factor VII Sales Quantity by Country (2018-2029)
       11.3.2 Middle East & Africa Human Coagulation Factor VII Consumption Value by Country (2018-2029)
       11.3.3 Turkey Market Size and Forecast (2018-2029)
       11.3.4 Egypt Market Size and Forecast (2018-2029)
       11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
       11.3.6 South Africa Market Size and Forecast (2018-2029)

12 Market Dynamics

   12.1 Human Coagulation Factor VII Market Drivers
   12.2 Human Coagulation Factor VII Market Restraints
   12.3 Human Coagulation Factor VII Trends Analysis
   12.4 Porters Five Forces Analysis
       12.4.1 Threat of New Entrants
       12.4.2 Bargaining Power of Suppliers
       12.4.3 Bargaining Power of Buyers
       12.4.4 Threat of Substitutes
       12.4.5 Competitive Rivalry
   12.5 Influence of COVID-19 and Russia-Ukraine War
       12.5.1 Influence of COVID-19
       12.5.2 Influence of Russia-Ukraine War

13 Raw Material and Industry Chain

   13.1 Raw Material of Human Coagulation Factor VII and Key Manufacturers
   13.2 Manufacturing Costs Percentage of Human Coagulation Factor VII
   13.3 Human Coagulation Factor VII Production Process
   13.4 Human Coagulation Factor VII Industrial Chain

14 Shipments by Distribution Channel

   14.1 Sales Channel
       14.1.1 Direct to End-User
       14.1.2 Distributors
   14.2 Human Coagulation Factor VII Typical Distributors
   14.3 Human Coagulation Factor VII Typical Customers

15 Research Findings and Conclusion

16 Appendix

   16.1 Methodology
   16.2 Research Process and Data Source
   16.3 Disclaimer

List of Tables

   Table 1. Global Human Coagulation Factor VII Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
   Table 2. Global Human Coagulation Factor VII Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
   Table 3. NovoNordisk Basic Information, Manufacturing Base and Competitors
   Table 4. NovoNordisk Major Business
   Table 5. NovoNordisk Human Coagulation Factor VII Product and Services
   Table 6. NovoNordisk Human Coagulation Factor VII Sales Quantity (K Mg), Average Price (USD/Kg), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 7. NovoNordisk Recent Developments/Updates
   Table 8. Global Human Coagulation Factor VII Sales Quantity by Manufacturer (2018-2023) & (K Mg)
   Table 9. Global Human Coagulation Factor VII Revenue by Manufacturer (2018-2023) & (USD Million)
   Table 10. Global Human Coagulation Factor VII Average Price by Manufacturer (2018-2023) & (USD/Kg)
   Table 11. Market Position of Manufacturers in Human Coagulation Factor VII, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2022
   Table 12. Head Office and Human Coagulation Factor VII Production Site of Key Manufacturer
   Table 13. Human Coagulation Factor VII Market: Company Product Type Footprint
   Table 14. Human Coagulation Factor VII Market: Company Product Application Footprint
   Table 15. Human Coagulation Factor VII New Market Entrants and Barriers to Market Entry
   Table 16. Human Coagulation Factor VII Mergers, Acquisition, Agreements, and Collaborations
   Table 17. Global Human Coagulation Factor VII Sales Quantity by Region (2018-2023) & (K Mg)
   Table 18. Global Human Coagulation Factor VII Sales Quantity by Region (2024-2029) & (K Mg)
   Table 19. Global Human Coagulation Factor VII Consumption Value by Region (2018-2023) & (USD Million)
   Table 20. Global Human Coagulation Factor VII Consumption Value by Region (2024-2029) & (USD Million)
   Table 21. Global Human Coagulation Factor VII Average Price by Region (2018-2023) & (USD/Kg)
   Table 22. Global Human Coagulation Factor VII Average Price by Region (2024-2029) & (USD/Kg)
   Table 23. Global Human Coagulation Factor VII Sales Quantity by Type (2018-2023) & (K Mg)
   Table 24. Global Human Coagulation Factor VII Sales Quantity by Type (2024-2029) & (K Mg)
   Table 25. Global Human Coagulation Factor VII Consumption Value by Type (2018-2023) & (USD Million)
   Table 26. Global Human Coagulation Factor VII Consumption Value by Type (2024-2029) & (USD Million)
   Table 27. Global Human Coagulation Factor VII Average Price by Type (2018-2023) & (USD/Kg)
   Table 28. Global Human Coagulation Factor VII Average Price by Type (2024-2029) & (USD/Kg)
   Table 29. Global Human Coagulation Factor VII Sales Quantity by Application (2018-2023) & (K Mg)
   Table 30. Global Human Coagulation Factor VII Sales Quantity by Application (2024-2029) & (K Mg)
   Table 31. Global Human Coagulation Factor VII Consumption Value by Application (2018-2023) & (USD Million)
   Table 32. Global Human Coagulation Factor VII Consumption Value by Application (2024-2029) & (USD Million)
   Table 33. Global Human Coagulation Factor VII Average Price by Application (2018-2023) & (USD/Kg)
   Table 34. Global Human Coagulation Factor VII Average Price by Application (2024-2029) & (USD/Kg)
   Table 35. North America Human Coagulation Factor VII Sales Quantity by Type (2018-2023) & (K Mg)
   Table 36. North America Human Coagulation Factor VII Sales Quantity by Type (2024-2029) & (K Mg)
   Table 37. North America Human Coagulation Factor VII Sales Quantity by Application (2018-2023) & (K Mg)
   Table 38. North America Human Coagulation Factor VII Sales Quantity by Application (2024-2029) & (K Mg)
   Table 39. North America Human Coagulation Factor VII Sales Quantity by Country (2018-2023) & (K Mg)
   Table 40. North America Human Coagulation Factor VII Sales Quantity by Country (2024-2029) & (K Mg)
   Table 41. North America Human Coagulation Factor VII Consumption Value by Country (2018-2023) & (USD Million)
   Table 42. North America Human Coagulation Factor VII Consumption Value by Country (2024-2029) & (USD Million)
   Table 43. Europe Human Coagulation Factor VII Sales Quantity by Type (2018-2023) & (K Mg)
   Table 44. Europe Human Coagulation Factor VII Sales Quantity by Type (2024-2029) & (K Mg)
   Table 45. Europe Human Coagulation Factor VII Sales Quantity by Application (2018-2023) & (K Mg)
   Table 46. Europe Human Coagulation Factor VII Sales Quantity by Application (2024-2029) & (K Mg)
   Table 47. Europe Human Coagulation Factor VII Sales Quantity by Country (2018-2023) & (K Mg)
   Table 48. Europe Human Coagulation Factor VII Sales Quantity by Country (2024-2029) & (K Mg)
   Table 49. Europe Human Coagulation Factor VII Consumption Value by Country (2018-2023) & (USD Million)
   Table 50. Europe Human Coagulation Factor VII Consumption Value by Country (2024-2029) & (USD Million)
   Table 51. Asia-Pacific Human Coagulation Factor VII Sales Quantity by Type (2018-2023) & (K Mg)
   Table 52. Asia-Pacific Human Coagulation Factor VII Sales Quantity by Type (2024-2029) & (K Mg)
   Table 53. Asia-Pacific Human Coagulation Factor VII Sales Quantity by Application (2018-2023) & (K Mg)
   Table 54. Asia-Pacific Human Coagulation Factor VII Sales Quantity by Application (2024-2029) & (K Mg)
   Table 55. Asia-Pacific Human Coagulation Factor VII Sales Quantity by Region (2018-2023) & (K Mg)
   Table 56. Asia-Pacific Human Coagulation Factor VII Sales Quantity by Region (2024-2029) & (K Mg)
   Table 57. Asia-Pacific Human Coagulation Factor VII Consumption Value by Region (2018-2023) & (USD Million)
   Table 58. Asia-Pacific Human Coagulation Factor VII Consumption Value by Region (2024-2029) & (USD Million)
   Table 59. South America Human Coagulation Factor VII Sales Quantity by Type (2018-2023) & (K Mg)
   Table 60. South America Human Coagulation Factor VII Sales Quantity by Type (2024-2029) & (K Mg)
   Table 61. South America Human Coagulation Factor VII Sales Quantity by Application (2018-2023) & (K Mg)
   Table 62. South America Human Coagulation Factor VII Sales Quantity by Application (2024-2029) & (K Mg)
   Table 63. South America Human Coagulation Factor VII Sales Quantity by Country (2018-2023) & (K Mg)
   Table 64. South America Human Coagulation Factor VII Sales Quantity by Country (2024-2029) & (K Mg)
   Table 65. South America Human Coagulation Factor VII Consumption Value by Country (2018-2023) & (USD Million)
   Table 66. South America Human Coagulation Factor VII Consumption Value by Country (2024-2029) & (USD Million)
   Table 67. Middle East & Africa Human Coagulation Factor VII Sales Quantity by Type (2018-2023) & (K Mg)
   Table 68. Middle East & Africa Human Coagulation Factor VII Sales Quantity by Type (2024-2029) & (K Mg)
   Table 69. Middle East & Africa Human Coagulation Factor VII Sales Quantity by Application (2018-2023) & (K Mg)
   Table 70. Middle East & Africa Human Coagulation Factor VII Sales Quantity by Application (2024-2029) & (K Mg)
   Table 71. Middle East & Africa Human Coagulation Factor VII Sales Quantity by Region (2018-2023) & (K Mg)
   Table 72. Middle East & Africa Human Coagulation Factor VII Sales Quantity by Region (2024-2029) & (K Mg)
   Table 73. Middle East & Africa Human Coagulation Factor VII Consumption Value by Region (2018-2023) & (USD Million)
   Table 74. Middle East & Africa Human Coagulation Factor VII Consumption Value by Region (2024-2029) & (USD Million)
   Table 75. Human Coagulation Factor VII Raw Material
   Table 76. Key Manufacturers of Human Coagulation Factor VII Raw Materials
   Table 77. Human Coagulation Factor VII Typical Distributors
   Table 78. Human Coagulation Factor VII Typical Customers

List of Figures

   Figure 1. Human Coagulation Factor VII Picture
   Figure 2. Global Human Coagulation Factor VII Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
   Figure 3. Global Human Coagulation Factor VII Consumption Value Market Share by Type in 2022
   Figure 4. Recombinant Factor VIII Examples
   Figure 5. Plasma-derived Factor VIII Examples
   Figure 6. Global Human Coagulation Factor VII Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
   Figure 7. Global Human Coagulation Factor VII Consumption Value Market Share by Application in 2022
   Figure 8. Hemophilia A Examples
   Figure 9. Spontanous / Trauma Examples
   Figure 10. Surgical Examples
   Figure 11. Others Examples
   Figure 12. Global Human Coagulation Factor VII Consumption Value, (USD Million): 2018 & 2022 & 2029
   Figure 13. Global Human Coagulation Factor VII Consumption Value and Forecast (2018-2029) & (USD Million)
   Figure 14. Global Human Coagulation Factor VII Sales Quantity (2018-2029) & (K Mg)
   Figure 15. Global Human Coagulation Factor VII Average Price (2018-2029) & (USD/Kg)
   Figure 16. Global Human Coagulation Factor VII Sales Quantity Market Share by Manufacturer in 2022
   Figure 17. Global Human Coagulation Factor VII Consumption Value Market Share by Manufacturer in 2022
   Figure 18. Producer Shipments of Human Coagulation Factor VII by Manufacturer Sales Quantity ($MM) and Market Share (%): 2021
   Figure 19. Top 3 Human Coagulation Factor VII Manufacturer (Consumption Value) Market Share in 2022
   Figure 20. Top 6 Human Coagulation Factor VII Manufacturer (Consumption Value) Market Share in 2022
   Figure 21. Global Human Coagulation Factor VII Sales Quantity Market Share by Region (2018-2029)
   Figure 22. Global Human Coagulation Factor VII Consumption Value Market Share by Region (2018-2029)
   Figure 23. North America Human Coagulation Factor VII Consumption Value (2018-2029) & (USD Million)
   Figure 24. Europe Human Coagulation Factor VII Consumption Value (2018-2029) & (USD Million)
   Figure 25. Asia-Pacific Human Coagulation Factor VII Consumption Value (2018-2029) & (USD Million)
   Figure 26. South America Human Coagulation Factor VII Consumption Value (2018-2029) & (USD Million)
   Figure 27. Middle East & Africa Human Coagulation Factor VII Consumption Value (2018-2029) & (USD Million)
   Figure 28. Global Human Coagulation Factor VII Sales Quantity Market Share by Type (2018-2029)
   Figure 29. Global Human Coagulation Factor VII Consumption Value Market Share by Type (2018-2029)
   Figure 30. Global Human Coagulation Factor VII Average Price by Type (2018-2029) & (USD/Kg)
   Figure 31. Global Human Coagulation Factor VII Sales Quantity Market Share by Application (2018-2029)
   Figure 32. Global Human Coagulation Factor VII Consumption Value Market Share by Application (2018-2029)
   Figure 33. Global Human Coagulation Factor VII Average Price by Application (2018-2029) & (USD/Kg)
   Figure 34. North America Human Coagulation Factor VII Sales Quantity Market Share by Type (2018-2029)
   Figure 35. North America Human Coagulation Factor VII Sales Quantity Market Share by Application (2018-2029)
   Figure 36. North America Human Coagulation Factor VII Sales Quantity Market Share by Country (2018-2029)
   Figure 37. North America Human Coagulation Factor VII Consumption Value Market Share by Country (2018-2029)
   Figure 38. United States Human Coagulation Factor VII Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 39. Canada Human Coagulation Factor VII Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 40. Mexico Human Coagulation Factor VII Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 41. Europe Human Coagulation Factor VII Sales Quantity Market Share by Type (2018-2029)
   Figure 42. Europe Human Coagulation Factor VII Sales Quantity Market Share by Application (2018-2029)
   Figure 43. Europe Human Coagulation Factor VII Sales Quantity Market Share by Country (2018-2029)
   Figure 44. Europe Human Coagulation Factor VII Consumption Value Market Share by Country (2018-2029)
   Figure 45. Germany Human Coagulation Factor VII Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 46. France Human Coagulation Factor VII Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 47. United Kingdom Human Coagulation Factor VII Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 48. Russia Human Coagulation Factor VII Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 49. Italy Human Coagulation Factor VII Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 50. Asia-Pacific Human Coagulation Factor VII Sales Quantity Market Share by Type (2018-2029)
   Figure 51. Asia-Pacific Human Coagulation Factor VII Sales Quantity Market Share by Application (2018-2029)
   Figure 52. Asia-Pacific Human Coagulation Factor VII Sales Quantity Market Share by Region (2018-2029)
   Figure 53. Asia-Pacific Human Coagulation Factor VII Consumption Value Market Share by Region (2018-2029)
   Figure 54. China Human Coagulation Factor VII Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 55. Japan Human Coagulation Factor VII Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 56. Korea Human Coagulation Factor VII Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 57. India Human Coagulation Factor VII Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 58. Southeast Asia Human Coagulation Factor VII Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 59. Australia Human Coagulation Factor VII Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 60. South America Human Coagulation Factor VII Sales Quantity Market Share by Type (2018-2029)
   Figure 61. South America Human Coagulation Factor VII Sales Quantity Market Share by Application (2018-2029)
   Figure 62. South America Human Coagulation Factor VII Sales Quantity Market Share by Country (2018-2029)
   Figure 63. South America Human Coagulation Factor VII Consumption Value Market Share by Country (2018-2029)
   Figure 64. Brazil Human Coagulation Factor VII Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 65. Argentina Human Coagulation Factor VII Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 66. Middle East & Africa Human Coagulation Factor VII Sales Quantity Market Share by Type (2018-2029)
   Figure 67. Middle East & Africa Human Coagulation Factor VII Sales Quantity Market Share by Application (2018-2029)
   Figure 68. Middle East & Africa Human Coagulation Factor VII Sales Quantity Market Share by Region (2018-2029)
   Figure 69. Middle East & Africa Human Coagulation Factor VII Consumption Value Market Share by Region (2018-2029)
   Figure 70. Turkey Human Coagulation Factor VII Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 71. Egypt Human Coagulation Factor VII Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 72. Saudi Arabia Human Coagulation Factor VII Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 73. South Africa Human Coagulation Factor VII Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 74. Human Coagulation Factor VII Market Drivers
   Figure 75. Human Coagulation Factor VII Market Restraints
   Figure 76. Human Coagulation Factor VII Market Trends
   Figure 77. Porters Five Forces Analysis
   Figure 78. Manufacturing Cost Structure Analysis of Human Coagulation Factor VII in 2022
   Figure 79. Manufacturing Process Analysis of Human Coagulation Factor VII
   Figure 80. Human Coagulation Factor VII Industrial Chain
   Figure 81. Sales Quantity Channel: Direct to End-User vs Distributors
   Figure 82. Direct Channel Pros & Cons
   Figure 83. Indirect Channel Pros & Cons
   Figure 84. Methodology
   Figure 85. Research Process and Data Source